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2 key points:  
- Biallelic EFL1 mutations cause Shwachman-Diamond syndrome 
- EFL1 deficiency impairs eIF6 eviction from nascent 60S ribosomal subunits, reducing ribosomal subunit joining 





Shwachman-Diamond syndrome (SDS) is a recessive disorder typified by bone marrow failure and 
predisposition to hematological malignancies. SDS is predominantly caused by deficiency of the 
allosteric regulator SBDS that cooperates with the GTPase EFL1 to catalyze release of the ribosome 
anti-association factor eIF6 and activate translation. Here, we report biallelic mutations in EFL1 in three 
unrelated individuals with clinical features of SDS. Cellular defects in these individuals include 
impaired ribosomal subunit joining and attenuated global protein translation as a consequence of 
defective eIF6 eviction. In mice, Efl1 deficiency recapitulates key aspects of the SDS phenotype. By 
identifying biallelic EFL1 mutations in SDS, we define this leukemia predisposition disorder as a 
ribosomopathy that is caused by corruption of a fundamental, conserved mechanism, which licenses 
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Introduction 
 Ribosomes are the essential macromolecular machines that carry out protein synthesis in all 
organisms. Eukaryotic ribosomes are formed by the association of the small 40S subunit (containing the 
18S ribosomal RNA (rRNA)) and the large 60S subunit (containing the 28S, 5.8S, and 5S ribosomal 
RNAs (rRNAs)) to form actively translating 80S ribosomes1. In humans, mutations in the ribosome 
assembly factors or ribosomal proteins themselves lead to disorders termed ribosomopathies2 that are 
associated with a range of clinical phenotypes including bone marrow failure, hematological 
malignancies and cancer2-4. 
 Shwachman-Diamond syndrome (SDS) is an autosomal recessive disorder associated with bone 
marrow failure and an increased risk of progression to hematological malignancies including 
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)5. SDS is also characterized by 
developmental anomalies including poor growth, exocrine pancreatic dysfunction, metaphyseal 
chondrodysplasia, and cognitive impairment6,7. In around 90% of cases, SDS is caused by biallelic 
mutations in the SBDS gene. Genetic, biochemical, and structural studies have revealed that the SBDS 
protein cooperates with elongation factor-like GTPase 1 (EFL1), a homolog of the ribosomal 
translocase elongation factor 2 (EF-2), during the terminal step in 60S subunit maturation to couple 
release of the ribosome anti-association factor eIF6 (yeast Tif6) to a final quality-control assessment of 
the integrity of the P-site and the GTPase center of the 60S subunit4. By binding to the sarcin-ricin loop 
and to ribosomal proteins uL3, uL14 and eL24 (using the new nomenclature8) on the intersubunit face 
of the 60S subunit, eIF6 forms a physical barrier to ribosomal subunit joining4,9,10 and must therefore be 
removed to activate translation. However, an alternative model posits that protein kinase C (PKC) and 
the receptor for activated protein C (RACK1) promote eIF6 eviction through phosphorylation of eIF6 
on residue S23511.  
 Around 10% of individuals with SDS lack mutations in the SBDS gene. The identification of 
biallelic mutations in DNAJC21 (yeast Jjj1) in a subset of SDS patients lacking mutations in the SBDS 
gene12-15 indicates that SDS is genetically heterogeneous. Jjj1 cooperates with the cytoplasmic zinc-
finger protein Rei1 (human ZNF622) to stimulate the ATPase activity of the Hsp70 chaperone Ssa 
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(human HSPA8), liberating the nuclear export factor Arx1 (human PA2G4) from its binding site near 
the peptide exit tunnel on the 60S subunit16-20. These data raise the possibility that additional 
components of the 60S subunit assembly pathway might also be mutated in SDS. 
 Here, we report the identification of biallelic mutations in the EFL1 gene in individuals with 
clinical features of SDS. We demonstrate that disease-associated EFL1 mutations disrupt eIF6 release 
from late cytoplasmic 60S subunits, thereby impairing ribosomal subunit joining and attenuating global 
translation. Furthermore, we show that Efl1-mutant mice recapitulate key aspects of the SDS phenotype. 
We define SDS as a ribosomopathy that is caused by corruption of a fundamental, conserved 
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Materials and Methods 
Patients. Informed consents were obtained from the families in accordance with the Declaration of 
Helsinki. This study was approved by the Institutional Review Board of INSERM and Assistance 
Publique des Hôpitaux de Paris.  
Cell culture. Detailed procedure is described in Supplementary data. 
Immunoblotting. Immunoblotting procedure is detailed in detailed in Supplementary data. Antibodies 
are listed in Supplementary Table 3.  
Whole exome sequencing. Whole exome sequencing procedure is detailed in Supplementary data. 
Targeted resequencing by NGS. Detailed procedure is described in Supplementary data.  
cDNA analysis.  Information on cDNA analysis is provided in Supplementary data.  
Constructs. The EFL1 open reading frame was PCR amplified and cloned into the lentiviral vectors 
p.lenti7.3/V5 TOPO (Invitrogen) and pCW57-GFP-P2A (Plasmid #71783; Addgene) for 
complementation experiments. 
Measurement of protein synthesis. Measurement of protein synthesis, detailed in Supplementary data  
was performed as described22.  
Sucrose density gradients. Ribosomal subunits were separated by sucrose density gradients as 
described23,24. Detailed information is provided in Supplemental Data.  
Cell fractionation. Detailed procedure is described in Supplementary data.  
eIF6 release assay. Detailed information is provided in Supplemental Data.  
EFL1 cloning, expression, and purification. Human EFL1 mutants were generated by PCR using the 
wild-type EFL1 cDNA (long isoform ENST00000268206.11). Detailed procedures are available in 
supplementary data.   
Statistics. Student's t test (two-tailed, type two) was used to determine significant differences. P < 0.05 
was considered significant. 
Mice. Detailed procedure is described in Supplementary data.  
Data sharing statement 
For original data, please contact either patrick.revy@inserm.fr or ajw1000@cam.ac.uk. 
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RESULTS 
Identification of biallelic EFL1 mutations in three unrelated individuals  
 In the course of a systematic survey of individuals presenting with inherited bone marrow 
failure syndrome (IBMFS), we performed whole exome sequencing (WES) analysis to identify rare 
biallelic variants predicted to be pathogenic (frequency less than 0.1% in 1000 genomes, EVS, dbSNP, 
and our in-house database (8319 individuals)). This approach identified a male (P1) carrying compound 
heterozygous mutations in the EFL1 gene (HGNC: 25789; Entrez Gene: 79631) encoding elongation 
factor-like GTPase 1 (EFL1) (Fig. 1a). Since EFL1 physically and functionally interacts with 
SBDS4,23,24,30, we considered EFL1 as a strong candidate gene. Sanger sequencing confirmed the 
presence of biallelic EFL1 mutations, including a nonsense mutation causing a premature stop codon on 
one allele (c.2260C>T; p.R754*) inherited from his healthy mother and also present in his healthy sister 
(Fig. 1a and Supplementary Fig. 1a), and a missense mutation leading to an amino acid substitution 
(c.1514T>C; p.F505S) on the allele inherited from his unaffected father (Fig. 1a and Supplementary 
Fig. 1a). EFL1 cDNA sequencing in P1 suggested reduced abundance of the allele carrying the 
c.2260C>T; p.R754* mutation, consistent with partial nonsense mediated decay (NMD) 
(Supplementary Fig. 1a). 
 In order to identify additional individuals potentially carrying biallelic EFL1 mutations, we 
analyzed the EFL1 gene by gene-targeted sequencing of a cohort of 30 individuals who were diagnosed 
clinically with SDS but lacked mutations in the SBDS gene. This approach identified an EFL1 
homozygous missense mutation (c.2908C>T; p.R970H) in a female (P2), born from a consanguineous 
family (Fig. 1b). Sanger sequencing confirmed the mutation and indicated that both parents and the 
healthy siblings were heterozygous for the mutant EFL1 allele (Fig. 1b and Supplementary Fig. 1b). 
In addition, we identified a third female (P3) carrying a heterozygous EFL1 missense mutation 
(c.2647T>G; p.C883G) (Fig. 1c). Sanger sequencing confirmed the mutation and indicated that it was 
inherited from her father and also carried by her healthy brother (Fig. 1c and Supplementary Fig. 1c). 
No other pathogenic exon-encoded variants were detected in individual P3. However, the near absence 
of detectable wild type EFL1 mRNA transcripts from the ‘normal’ allele in P3's cells suggests a 
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noncoding defect in the allele inherited from her mother that affects EFL1 expression (Fig. 1c, Zoom). 
Sequence analysis of genomic DNA (gDNA) and cDNA of a synonymous single nucleotide variant 
(SNV) present in a heterozygous state in the EFL1 coding sequence (rs4725) from control, P3 and P3’s 
mother confirmed the defective expression of one EFL1 allele in both P3 and her mother 
(Supplementary Fig. 2a). Furthermore, immunoblotting analysis demonstrated reduced EFL1 protein 
expression in B-LCL lysates from the mother of P3 compared with control, confirming the genetic 
results (Supplementary Fig. 2b). Haplotype analysis of the EFL1 locus in P3's family indicated that 
P3's brother, unlike his sister, inherited the wild type maternal EFL1 allele (Supplementary Fig. 2c). 
However, whole EFL1 gene sequencing did not identify obvious genetic variants that could explain the 
defective expression of EFL1 from the maternal allele. Nonetheless, biochemical analysis confirmed a 
functional EFL1 defect in individual P3 (see below). 
 The four identified EFL1 mutations affected both the long (ENST00000268206.11) and short 
(ENST00000359445.7) EFL1 isoforms. Furthermore, they were absent or extremely rare in the gnomAD 
Browser (Supplementary Table 1) and in-silico tools (SIFT31; Polyphen232, CADD33) and the ACMG 
standards34 predicted the EFL1 coding variants to be deleterious (Supplementary Table 1). Moreover, 
the three missense mutations affect highly conserved amino acids across species (Fig. 1d). Interestingly, 
the EFL1 p.F505S mutation maps to a key functional dynamic interface between EFL1 domains II-III 
(Fig. 1e,f) that mediates EFL1 conformational change on the ribosome4. In yeast, mutations that map to 
the EFL1 domain II-III interface likely suppress mutations in the P-site loop of uL16 (RPL10) by 
promoting conformational changes similar to those undergone by eukaryotic EF-2 and EF-G during 
translocation35. Both the p.C883G and p.R970H missense mutations map to the interface between EFL1 
domain IV (Fig. 1e,f) and the C-terminal domain III of SBDS (Fig. 2). In yeast, domain IV is essential 
for Efl1 function in vivo35. Based on these observations, we hypothesized that the p.F505S, p.R970H 
and p.C883G mutations impair EFL1 function and that there is a causal link between the EFL1 
mutations identified and the SDS phenotype.  
 
Clinical features of EFL1-deficient individuals 
 P1 is a male from a French family (Table 1) who was born at term with a birth weight of 2,480 
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g (<3.0 percentile) and height 47 cm (3.0 percentile). He initially presented with unsteady gait. He 
sustained a spontaneous femoral fracture at 5 years of age and required surgical correction of severe 
genu valgum at 12 years of age. Metaphyseal chondrodysplasia was noted on X-ray at 13 years of age  
(Supplementary Fig. 3a). At 17 years of age, he developed mild thrombocytopenia and subsequently 
progressive leukopenia with neutropenia and mild anemia (Supplementary Fig. 3b). At 27 years of 
age, he developed chronic diarrhea, with reduced fat-soluble vitamins and fecal elastase, consistent with 
exocrine pancreatic dysfunction. He developed portal hypertension and splenomegaly secondary to liver 
cirrhosis. Despite mild intellectual impairment, he was able to perform daily work. At 31 years of age, 
the bone marrow trephine was hypocellular, with typical hyposegmented neutrophils observed in 
SDS5,36 (Table 1 and Supplementary Fig. 3c). No clonal cytogenetic abnormality was detected.  
 P2, a girl, is the third child in a consanguineous family of four (Table 1). She was born at 40 
weeks of gestation with a birth weight of 2,640 g (2.5 centile), height 46 cm (1.7 centile) and a head 
circumference of 32.5 cm (6.8 centile). She presented at 13 months of age with failure to thrive, 
anorexia, moderately elevated liver enzymes, reduced zinc and vitamin A levels and mild iron 
deficiency anemia (Table 1 and Supplementary Fig. 3b). Although anti-gliadin antibodies were 
positive at 8 months of age, they were later negative. At 18 months of age, ataxia and nystagmus were 
observed. She developed mild iron deficiency anemia (corrected with oral iron supplementation) and 
mild thrombocytopenia. At 3.8 years of age, she was neutropenic and thrombocytopenic 
(Supplementary Fig. 3b). In addition, exocrine pancreatic deficiency was noted, based on low fecal 
elastase and fat-soluble vitamins (A and E). Abdominal CT scan showed no evidence of pancreatic 
lipomatosis. Bone marrow examination revealed hyposegmented neutrophils (Table 1 and 
Supplementary Fig. 3c). She failed to achieve developmental milestones. Her visual acuity was very 
low (2/10 of both eyes) due to severe myopia (with no associated retinal abnormalities). She had normal 
social behavior with a normal WISC IV test37 at 10 years of age. However, her academic progress was 
delayed by 2 years at a Special School for the Blind. Although skeletal X-rays were normal, she 
exhibited growth delay due to deficiency of growth hormone (GH), which was introduced at the age of 
11 years. From 8-11 years of age, her growth rate decreased from -1.8 SD to -3 SD (height 125 cm), 
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when GH therapy was initiated. Two years later, her height was 138 cm (- 2.7 SD), but puberty had not 
started.   
 P3, a girl, is a second child from a non-consanguineous French family (Table 1). The older 
child and the parents are healthy. Growth delay and femoral shortening was noticed in utero at 32 weeks 
of gestation. Following a caesarean section at 39 weeks gestational age due to an abnormal cardiac 
rhythm, her birth weight was 2,160 g (0.1 centile), height 45 cm (1.2 centile) and pectus carinatum and 
short limbs were noted. Severe neonatal anemia and thrombocytopenia with abnormal liver function 
tests (3 x normal value) were observed at day 2. Transfusion-dependent anemia persisted until 2 years of 
age (Supplementary Fig. 3b) with erythroblastopenia and hyposegmented neutrophils in the bone 
marrow (Table 1 and Supplementary Fig. 3c). Pancreatic insufficiency was diagnosed at 3 months of 
age, with chronic diarrhea, reduced fecal elastase and fat-soluble vitamins (A and E). Due to persistent 
anorexia, a gastrostomy was performed at 8 months of age and is still present at 5 years of age.  At 2 
years of age, she became red cell transfusion independent. Growth retardation persisted with a height of 
88 cm (-6 SD) at age 7 years. She has major skeletal defects involving the vertebrae, limbs and ribs, 
including metaphyseal chondrodysplasia (Supplementary Fig. 3a). She has good social skills but 
impaired cognitive development and is currently attending a Special School with 3 years delay.  
 In summary all three individuals (P1, P2, and P3) exhibited hematological abnormalities, short 
stature and exocrine pancreatic insufficiency consistent with the clinical diagnosis of SDS. However, all 
three individuals were negative for mutations in the SBDS gene.  
 
Impaired eIF6 release and attenuated translation in cells from EFL1-mutant individuals 
 EFL1 cooperates with its cofactor SBDS to evict eIF6 from the nascent 60S ribosomal subunit 
during the terminal step in cytoplasmic maturation4. We therefore set out to obtain in vivo evidence for 
impaired eIF6 recycling, defective ribosomal subunit joining, and impaired global protein translation in 
cells from individuals carrying EFL1 mutations. Immunoblotting revealed that EFL1 protein in cell 
lysates from P1 and P3's fibroblasts was reduced to 15 % and 5 % respectively of wild type levels (Fig. 
3a). Thus, biallelic EFL1 mutations in individual P1 reduced the expression and/or stability of the 
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encoded EFL1 protein. Importantly, the low abundance of EFL1 in P3's fibroblast lysates confirmed the 
sequencing results obtained from P3-derived EFL1 cDNA (Fig. 1a, zoom and Supplementary Fig. 2). 
In contrast, the expression of EFL1 was not affected by the p.R970H mutation present in P2's fibroblasts 
(Fig. 3a). Similar findings were made in B-LCL lysates from the same individuals (Fig. 3b). 
Furthermore, the expression of additional factors involved in terminal cytoplasmic ribosomal maturation 
(NMD3, DNAJC21, PA2G4, eIF6, and SBDS) was unaffected in EFL1-deficient cells (Fig. 3a,b).  
 Next, we tested if EFL1 mutations affect EFL1 function in ribosomal biogenesis. Consistent 
with a defect in ribosomal subunit joining, sucrose gradient centrifugation analysis of lysates from 
EFL1 mutant fibroblasts revealed an increased ratio of 60S:80S ribosomal subunits relative to control 
(Fig. 3c,d). The severity of the ribosomal subunit joining defect correlated with the level of residual 
EFL1 protein expression in P1 and P3's lysates (Fig. 3a,b). Although the expression of mutant EFL1 
protein in P2's cells is similar to wild type, the increased 60S:80S ratio in these cells indicates that there 
is functional impairment of the mutant EFL1 protein.  
 In wild type cells, eIF6 binds to pre-60S ribosomal subunits in the nucleus and shuttles to the 
cytoplasm, where it is released during the terminal step in 60S subunit maturation. Thus, eIF6 is 
distributed between both the nuclear and cytoplasmic compartments. Compared with controls, the 
amount of eIF6 in the nucleus of EFL1 mutant fibroblasts was reduced by 70-80% (Fig. 3e,f), consistent 
with a role for human EFL1 in promoting efficient nuclear recycling of eIF6.    
 As ribosomal subunit joining is impaired in EFL1 mutant fibroblasts derived from all three 
patients, we anticipated that global protein synthesis would be attenuated in these cells. Indeed, protein 
synthesis was reduced in fibroblasts from P1 (62 %), P2 (50 %) and P3 (51 %) as assessed by in vivo 
incorporation of O-propargyl-puromycin (OP-Puro) (Fig. 3g,h)22,40. To further link this translational 
defect with the EFL1 mutations, we cloned the wild type EFL1 coding sequence into a lentiviral vector 
and transduced the EFL1 mutant fibroblasts from P1 and P3. The ectopic expression of wild type EFL1 
improved the translation rate in cells derived from P1 and P3 (Fig. 3i,j). Likewise, the inducible 
expression of wild type EFL1 in cells from P1, P2, and P3 (Fig. 3k) improved both the ribosomal 
subunit joining defect as assessed by the 60S:80S ratio following sucrose gradient centrifugation (Fig. 
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3l,m) and global translation (Fig. 3n), as assessed by incorporation of the methionine analog 
azidohomoalanine (AHA)22. Lastly, we assessed the functional impact of the EFL1 missense mutations 
identified in P1, P2 and P3 by biochemically reconstituting eIF6 release ex vivo from human pre-60S 
ribosomal subunits. We added recombinant human wild type or mutant EFL1 proteins together with 
SBDS and GTP to eIF6-loaded pre-60S subunits extracted from P3-derived human fibroblasts and 
monitored eIF6 removal by immunoblotting the “free” and “bound” fractions after pelleting the 
ribosomal subunits through a sucrose cushion (Fig. 3o). Recombinant wild type EFL1 efficiently 
triggered eIF6 release (Fig. 3p). The p.C883G EFL1 mutant identified in individual P3 did not 
significantly impair eIF6 release compared with wild type EFL1 (Fig. 3p), suggesting that the combined 
defects in the polysome profile (fig. 3c,d), eIF6 subcellular localization (fig. 3e,f) and translation (fig. 
3g,h) observed in the cells from P3 are a consequence of the strong reduction in EFL1 protein 
expression (Fig. 3a,b). In sharp contrast, both the p.F505S and p.R970H EFL1 mutants identified in P1 
and P2, respectively, yielded a markedly reduced amount of eIF6 in the free fraction compared with 
wild type, indicating that their ability to remove eIF6 is impaired (Fig. 3p).  
 We conclude from these results that the SDS-associated EFL1 mutations that we have identified 
are hypomorphic and cause the SDS phenotype by impairing (not completely abrogating) eIF6 release 
from late cytoplasmic 60S ribosomal subunits, thereby disrupting ribosomal subunit joining and 
attenuating global protein synthesis.  
 
Efl1-mutant mouse recapitulates the Shwachman-Diamond syndrome phenotype 
 To further assess the pathogenic effects of EFL1 mutations in vivo, we analyzed the Efl1-K983R 
mouse line (henceforth named Efl1K983R/K983R) generated by N-ethyl-N-nitrosourea (ENU)-induced 
mutagenesis26. Although the mouse mutation was not identified in any of the patients, Efl1 residue 
K983 (human K976) is highly conserved (Fig. 4a) and lies within domain IV of EFL1, in close 
proximity to human residues R970 and C883 mutated in P2 and P3, respectively (Fig. 1f). Most 
importantly, similar to the mutations identified in P1 and P3, the p.K983R substitution in the mouse 
causes a reduction in EFL1 protein expression as determined by immunoblotting (Fig. 4b,c) while the 
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total levels of eIF6 and SBDS were unaffected (data not shown). At the functional level, the murine 
p.K983R mutation also increased the 60S:80S ratio (Fig. 4d,e) although the relative rate of protein 
synthesis was not significantly affected (Fig. 4f). We conclude that the mouse p.K983R mutation is a 
valid model in which to study the broad phenotypic effects of EFL1 loss of function.  
 Efl1K983R/K983R mice were born at a normal Mendelian ratio and did not show any obvious 
pathological abnormalities after necropsy, including analysis of pancreas, liver, skeletal muscle and 
brain. However, the mice exhibited a significant reduction in weight compared with wild type or 
Efl1K983R/wt mice (Fig. 4g), due to a progressive decrease in fat mass accumulation (Fig. 4h). Although 
X-rays revealed no structural abnormalities of the skeleton in the Efl1K983R/K983R   mice (data not shown), 
bone mass density was significantly reduced compared with wild type littermates at different ages (Fig. 
4i). At the hematological level, compared with wild type mice, the bone marrow cellularity (Fig. 5a) as 
well as the frequency and absolute numbers of hematopoietic stem and progenitor cells (including 
pMegE, MkP and pGM/GMP progenitors29) were reduced in Efl1K983R/K983R mice (Fig 5b, c and 
supplementary figure 4). Additionally, we noticed a significant reduction in hemoglobin (Fig. 5d), 
platelet (Fig. 5e), and total white cell counts (Fig. 5f) in Efl1 K983R/K983R mice.  
 Some of the EFL1-deficient individuals suffered from motor abnormalities and cognitive 
deficits, also present in the Efl1K983R/K983R mutant mice. Indeed, we identified gait abnormalities (Fig. 5g) 
and motor dysfunction (Fig. 5h) when compared with littermate controls. Moreover, working memory 
was also disrupted in Efl1K983R/K983R mice, as tested via Y maze habituation (Fig. 5i).  
 We conclude from these observations that Efl1K983R/K983R   mutant mice recapitulate key aspects 
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DISCUSSION 
 In this study, we provide compelling evidence that recessive EFL1 mutations cause SDS by 
impairing release of eIF6 from nascent cytoplasmic 60S ribosomal subunits, thereby disrupting 
ribosomal subunit joining and attenuating global protein synthesis. Taken together with previous 
work23,24,30, our human genetic and biochemical data indicate that the release of eIF6 by the concerted 
action of EFL1 and its allosteric activator SBDS is a fundamental conserved mechanism that licenses 
the entry of functionally competent large ribosomal subunits into active translation. These data do not 
support a critical role for RACK1 and PKCβII in the eviction of eIF6 in mammalian cells through the 
phosphorylation of eIF6 residue S235 as previously proposed11. Indeed, the position of RACK1 on the 
head of the 40S subunit41, the viability and normal growth of PKCβ null mutant mice42 and the 
observation that the phylogenetically conserved eIF6 residues 1-224 are sufficient for eIF6 recycling in 
vivo4 are inconsistent with such a model. Our work provides the most compelling evidence to date that 
SDS is a ribosomopathy that is caused by mutations in multiple components (SBDS, EFL1 and 
DNAJC21) of a coherent pathway involved in cytoplasmic maturation of the 60S ribosomal subunit 
maturation. 
 Through our analysis, we identified an EFL1 pseudogene (EFL1P1; Chromosome 15: 
84,080,168-84,126,604) that is located 1.8 Mb distal to the EFL1 gene and is directionally inverted 
(Supplementary Fig. 5a). This is striking because in 89% of cases, SBDS mutations arise from a gene 
conversion event due to recombination between SBDS and its pseudogene (SBDSP), located 5.8 Mb 
distally in an inverted orientation43,44. Thus, the c.1514T>C (p.F505S) mutation identified in P1 might 
arise from gene conversion due to recombination between EFL1 and the EFL1P1 pseudogene 
containing this sequence change (Supplementary Fig. 5b,c). The genetic analysis of EFL1 is further 
challenged by the existence of a second EFL1 pseudogene (EFL1P2) located on a distinct chromosome 
(Chromosome 4: 65,142,703-65,145,763), as well as several segmental duplications located on 
chromosomes 15 and Y (Supplementary Table 2). These numerous genomic sequences that are highly 
homologous to the EFL1 gene may hamper the identification of pathological variants in EFL1. 
Furthermore, an uncharacterized genetic event in P3 has resulted in a profound reduction in EFL1 
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expression from the maternal allele (Fig. 1a, zoom and Supplementary Fig. 2)45,46. This observation 
suggests that analysis of the EFL1 coding sequence in SDS patients who lack SBDS mutations may be 
insufficient to detect the genetic events leading to defective EFL1 expression. We therefore recommend 
that EFL1 mutation status and EFL1 protein expression should be routinely assessed in individuals with 
SDS lacking mutations in SBDS and DNAJC21.  
 During the course of our study, Stepensky et al. and Tan et al. investigated a total of six 
individuals carrying biallelic variants in the EFL1-encoding gene47,48. However, the pathological 
significance of these mutations remains unclear as introduction of the corresponding disease-related 
variants in yeast had no significant effect on cell fitness47 and the functional impact of the reported 
EFL1 missense variants on human ribosome assembly and translation was not assessed47,48.  
 Autosomal dominant mutations in SRP54, a key member of the cotranslational protein-targeting 
pathway, results in neutropenia associated with SDS-like features such as pancreatic insufficiency and 
short stature49,50. However, myeloid maturation arrest at the promyelocyte stage and the presence of 
prominent cytoplasmic vacuoles in the myeloid precursors are not typical of classical SDS. Thus, the 
mechanism underlying the neutropenia may differ in patients with SRP54 mutations compared with that 
in typical SDS patients. 
 Structural, biochemical and genetic studies4,23,24,30,51 support a cofactor-dependent 
conformational-switching mechanism for release of the anti-association factor eIF6 from the 
intersubunit face of the 60S subunit. This model proposes that SBDS drives the conformational 
equilibrium of EFL1 towards a high affinity state that effectively competes with eIF6 for an overlapping 
binding site on the sarcin-ricin loop of the 60S subunit to promote eIF6 displacement. Supporting this 
hypothesis, cells derived from individuals carrying EFL1 mutations exhibit defects in eIF6 release and 
recycling, ribosomal subunit joining and protein translation that were corrected by expressing the wild 
type EFL1 protein (Fig. 3). The EFL1 p.C883G (P3) and murine p.K983R (human K976) mutations 
appear to simply reduce EFL1 expression. However, the EFL1 p.R970H mutation (P2) that is expressed 
at wild type levels is functionally defective. Interestingly, like residues C883 and K970, K976 maps to 
the interface between EFL1 domain IV (essential for Efl1 function in vivo in yeast35) and the C-terminal 
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domain of SBDS (Fig. 1f), where it may potentially disrupt the allosteric activation of EFL1 by SBDS. 
Furthermore, the EFL1 variants p.M882K and p.R1095Q reported by Stepensky et al47, map to this 
interface. The EFL1 p.F505S mutation (P1) is also functionally impaired, likely disrupting a key 
dynamic interface between EFL1 domains II-III that mediates EFL1 conformational change on the 
ribosome4. However, further investigations are required to precisely delineate the underlying 
mechanisms.  
 We reinforce these data by characterizing a novel mouse model carrying a point mutation within 
the Efl1 gene. Like the human EFL1 mutations identified here, the EFL1 p.K983R mouse mutation 
leads to reduced EFL1 protein expression, resulting in defects in ribosomal maturation. The mutation 
models key aspects of the human disease, including hematological abnormalities and growth deficits, as 
well as the defects in motor and cognitive function that are also present in some of the patients 
identified here, strongly supporting the conclusion that the SDS phenotype is caused by loss of EFL1 
function. 
 How do we explain the striking tissue proclivity in SDS? Our data demonstrate that similar to 
SBDS deficiency30,38,39, impaired EFL1 function markedly attenuates global protein synthesis by 
impairing ribosomal subunit joining due to the reduced availability of free cytoplasmic 60S ribosomal 
subunits. Therefore, the SDS phenotype likely reflects at least in part the impaired capacity of specific 
tissues to upregulate global protein translation at key time-points during development (and indeed 
postnatally) due to inefficient recruitment of nascent 60S subunits into the actively translating pool. 
Impaired translation re-initiation of complex mRNAs carrying upstream open reading frames may also 
contribute to the SDS phenotype52.  
 Tissue-specific sensitivities to cellular stress responses evoked by altered ribosome homeostasis 
may not only contribute to the SDS disease phenotype54 but may also potentially drive cancer 
progression by promoting the selection of compensatory mutations55. Thus, the somatic acquisition of 
biallelic TP53 variants in SBDS-deficient hematopoietic stem and progenitor cells is associated with 
clonal progression and transformation to poor prognosis MDS5,55. Furthermore, recurrent acquired 
interstitial deletions of chromosome 20 in SDS bone marrow cells encompass the EIF6 gene56,57, 
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providing a potential mechanism that allows SDS cells to bypass the defect in ribosomal subunit joining 
by reducing the cellular dose of eIF6. Whether eIF6 deletion indeed modulates the risk of acquiring 
somatic TP53 variants and progression to MDS and AML is an interesting question that will require 
careful clinical follow up of all genetic subgroups of SDS. Our data support the hypothesis that the 
development of small molecules that mimic the effect of TIF6 suppressor mutations in yeast30 may have 
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Figure Legends 
Figure 1. Identification of EFL1 mutations in three individuals with SDS. Family pedigrees and 
direct Sanger sequencing of the EFL1 gene in individuals 1 (P1) (a), 2 (P2) (b) and 3 (P3) (c). Arrows 
indicate the position of the mutations. (d) Multiple sequence alignment of EFL1 proteins from 
representative species. Identical amino acids are shown in red with white characters; similar amino acids 
are in red character; blue frame represents similarity across groups. (e) Schematic of the domain 
architecture of human EFL1 showing the position of disease-associated mutations. Domains I-V are 
indicated; id, insertion domain (residues 424-502), distinguish EFL1 from other translational GTPases. 
(f) Mapping of SDS-associated mutations onto human EFL1 (pdb 5anc4), shown in ribbon 
representation. Domains are colored deep salmon (I), light orange (id, II), cyan (III) and light blue (IV). 
Residue K976 corresponds to K983 mutated in the ENU mutant mouse model (see below). 
Figure 2. SDS-associated EFL1 mutations map to key functional interfaces. SBDS C-terminal 
domain, magenta, space-filling representation; EFL1, cyan; eIF6, yellow (pdb code 5anb), ribbon 
representation. EFL1 domains II, III and IV are indicated. EFL1 residues targeted by mutations that map 
to the interface with SBDS are encircled. Residues mutated in SDS are indicated in black (this study) or 
red (Stepensky et al.47) text; residue K976 (cyan), targeted in the mouse model (this study). H69, rRNA 
helix 69. 
Figure 3. SDS-associated EFL1 mutations impair eIF6 release.  (a) Total cell lysates from 
fibroblasts and (b) B-LCL from wild type (wt) and three individuals (P1, P2 and P3) with SDS were 
immunoblotted to visualize the indicated proteins. (c) Defective ribosome assembly in EFL1 mutant 
fibroblasts. Polysome profiles from fibroblast extracts from three unrelated individuals with SDS 
compared with wild type control. Quantification of the 60S:80S ribosomal subunit ratios is indicated as 
a bar chart (n≥5) (d). EFL1 genotypes are provided in Suppl. Table 1. (e) EFL1 is required for eIF6 
recycling in human cells. Indicated proteins were visualized by immunoblotting in cytoplasmic or 
nuclear fractions from wild-type and EFL1 mutant fibroblasts. Histone H3, nuclear marker; HSP9, 
cytoplasmic marker. (f) Relative amount of eIF6 in the nucleus of EFL1 mutant cells compared with 
wild type (n=5). (g, h) EFL1 deficiency attenuates protein synthesis. OP-Puro incorporation in 
fibroblast cells lines from individuals P1, P2 and P3 relative to wild type control cells quantified 1 hr 
after OP-Puro administration (n=6). (i) Complementation of EFL1-deficient fibroblasts with wild type 
EFL1. Lysates from EFL1 mutant fibroblasts transduced with a vector expressing GFP alone (+ empty) 
or GFP + EFL1 (+EFL1) and from wild type (WT) fibroblasts as a control. The indicated proteins were 
visualized by immunoblotting. (j) Wild type EFL1 rescues global translation in patient fibroblast cell 
lines from P1 and P3 (n=4). (k) Complementation of EFL1-deficient fibroblasts with inducible vector 
allows wild type EFL1 expression after doxycycline (Dox) treatment. Lysates from EFL1 mutant 
fibroblasts transduced with an empty vector, or EFL1-expressing vector with (+) or without (-) Dox. 
Vinculin is used as a loading control. (l) Comparison of polysome profiles from wild type and EFL1-
mutant fibroblasts transduced with empty vector or with inducible EFL1-expression vector treated (+) 
or not (-) with Dox. Arrows indicate increased 80S formation in complemented cells from individuals 
P1, P2 and P3. (m) Quantification of the 60S:80S ribosomal subunit ratios in cells transduced with 
inducible EFL1-expression vector treated (+) or not (-) with Dox (n=3). (n) Inducible expression of wild 
type EFL1 rescues global protein translation rates in EFL1-deficient fibroblast cell lines (n=6). (o) 
Schematic of eIF6 release assay. Pre-60S subunits extracted from P3-derived fibroblasts were incubated 
with the indicated release factors and pelleted through a 15% sucrose cushion. Immunoblotting reveals 
the eIF6 distribution in the supernatant (‘free”) and pellet (“bound”). (p) Release of eIF6 by SDS-
associated EFL1 variants. P3-derived pre-60S subunits were incubated with GTP, SBDS and the 
indicated EFL1 variants. EDTA was added as a positive control for eIF6 release. eIF6 and uL14 were 
visualized by immunoblotting. (-) indicates the negative control lacking EFL1. All data represent mean 
± s.e. Statistical significance between samples was assessed by two-tailed Student’s t-test. 
 
Figure 4. Efl1 K983R mutation leads to pleiotropic effects in mice. (a) Multiple sequence alignment 
of EFL1 proteins from representative species indicates that the murine EFL1 K983R mutation targets a 
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highly conserved residue. Identical amino acids are indicated by a red box with white characters; similar 
amino acids are in red characters; blue frame represents similarity across groups. (b) Representative 
total cell lysates of MEFs from wild type (Efl1+/+), heterozygous Efl1+/K983R and homozygous Efl1K983R 
/K983R mice were immunoblotted to visualize EFL1 protein. GAPDH is used as a loading control. (c) 
Quantifications show the EFL1/GAPDH ratio. (d) Representative polysome profiles of MEF extracts 
from Efl1K983R /K983R (n=4) and heterozygous Efl1+/K983R (n=9) mice compared with wild type control 
(Efl1+/+) (n=9). (e) Quantification of the 60S:80S ribosomal subunit ratios is indicated as a bar chart 
(n≥4). (f) Global protein translation rates in MEF from Efl1 K983R /K983R and heterozygous Efl1+/K983R mice 
compared with wild type control (Efl1+/+) (n=6). EFL1 K983R mutation reduces body weight from 3 
weeks of age (g), affecting the percentage of fat mass (h) and bone mass density (i) from 3 months of 
age. For all tests, p values are indicated. 
 
Figure 5. Impaired hematopoiesis, motor abnormalities and cognitive deficits in Efl1K983R/K983R mice. 
(a) Bone marrow cellularity in wild type and homozygous Efl1 K983R /K983R mice is indicated. (b, c) 
Frequencies of hematopoietic stem cells (HSC), megakaryocyte, granulocyte, erythroid progenitors 
(pMeGE), megakaryocyte progenitors (MkP), myeloid progenitors (preGM/GMP), and erythroid 
progenitors (pCFU-E and CFU-E) in the bone marrow in the indicated genotypes are shown (n=8 per 
genotype)29. EFL1 K983R mutation affects hematopoiesis. Hemoglobin levels (d), platelets (e), and 
total white blood cell counts (f). (g) Gait abnormalities in K983R mutant mice. Gait was analyzed using 
a qualitative scoring system at selected time points. Scores are explained in materials and methods. (h) 
Motor deficits in EFL1 K983R mutant mice. Free wheel running activity (over 7 nights, 3 months of 
age) for the indicated genotypes. (i) Cognitive deficits in K983R mutant mice. Y maze habituation 
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Table  
Table 1. Individuals with EFL1 mutations meet clinical criteria for SDS.  
Gender M F F 
Geographic origin France Africa Guinea France 
Consanguinity No Yes No 
Birth features At term At term At term 
Weight 2,840 (<3 percentile) 2,640 g (2.5 
centile) 
2,100 g (0.1 centile) 
Height  47 cm (3 percentile) 46 cm   (1.7 
centile) 
45 cm  (1.2 centile) 
Head circumference NA 32.5 cm (6.8 
centile) 
NA 
Evidence of bone 
marrow failure 
   
Initial manifestation 
and age at 
presentation 
Thrombocytopenia, age 17 years Failure to thrive, 
age 1.5 years 
Anemia, failure to thrive age 
1.2 months 




1.05 (1.0-3.9) 8.2 (1.0-37) 2.48 (1.83-4.0) 
G-CSF No No No 
Red cell transfusion No No Yes, during first year 
Hemoglobin (g/L). 
Median (min-max) 
118 (75-144) 104 (85-137) 114 (74 -182) 
Thrombocytopenia Severe Mild During follow up, 
thrombocytopenia (51x109/L) 
was observed only once, 
without hemorrhagic 
symptoms. Count recovered 
spontaneously. 
Platelets  (x109/L). 
Median (min-max) 
32 (13-168) 110 (47-231) 201 (51-326) 
Reticulocytes 
(x109/L) 
109 72 73 
MCV (fL)  90 94 103 
HbF (%)    NA 5.8  (age 8 years) NA 
Platelet transfusion No No No 
Pancytopenia Yes, after age 30 years No No 
Bone marrow 
cellularity 
Low (<5%). Two bone marrows (at 
age 28 years) reviewed. No myeloid 
maturation arrest. Segmentation 
defect in 8-22% of mature 
neutrophils. 
Low. At age 8 
years, no myeloid 
maturation arrest. 
Segmentation 
defect in 35% of 
mature neutrophils. 
Normal in the first year of 
life, mildly decreased on the 3 
bone marrow smears > 1 year 
old. Erythroblastopenia age 4 
months. No myeloid 
maturation arrest age 5 years, 
no erythroblastopenia. 








Yes, age 27 years Yes, age 5 years Yes, age 6 months 





Yes Yes Yes 
Pancreatic enzyme 
therapy 
Yes Yes Yes 
Pancreatic MRI Lipomatosis No lipomatosis No MRI, but hyper-
echogenicity on US 
Chronic diarrhoea Yes Yes Yes 
Faecal elastase Low (<200 μg/g feces) Low (< 200 μg/g 
feces) 
Very low (<100 μg/g feces) 
Vitamin A Normal Low Low 
Vitamin D Normal Normal Normal 
Vitamin E NA Normal Normal 
Liver Portal hypertension with 
splenomegaly. Fibrosis evaluated on 
CT scan and liver biopsy age 29 
years. Virology negative 








Normal liver MRI. Elevated 
liver enzymes AST/ALT, (60-
120 IU/L). No biopsy. 
Skeletal 
abnormalities 
Claudication and atraumatic femoral 
neck fracture at 5 years of age.Severe 
osteoporosis, poly-epiphyseal and 
metaphyseal dysplasia with major 
bilateral genu valgum, patellar 
luxation, hip subluxation and bilateral 
oval femoral heads. Surgery for genu 
valgum complicated by osteitis, but 
outcome was favorable. Coxa plana 
and metaphyseal chondrodysplasia 
noted at age 29 years. 
No abnormalities Metaphyseal 
dysplasia.Skeletal defects of 
the vertebrae, limbs and ribs. 
Pectus carinatum 
Bone density Low, T score (vertebrae) -3.2 SD Not evaluated Not evaluated 
Growth 
impairment 
Short stature -2.6 SD. No therapy Short stature -3 SD 





Short stature -6 SD (not 
improved by pancreatic 
enzyme replacement). GH 
deficiency. No therapy 
Eyes Normal Very severe 
myopia with low 
visual acuity 
Normal 





Normal Mild. 2 year delay 
at a special school 
for learning 
disabilities. Speech 
delay but at age 10 
years, WISC- IV 
test1 normal for 
age 
Mild. 3 years delay in special 






MRI normal but 
Chiari type I 
malformation 
diagnosed at 2 yrs 
None. CNS MRI normal. 
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Dentition Abnormal tooth enamel Numerous dental 
caries 
Normal 
Skin abnormalities No No No 
Recurrent 
bacterial Infections 
No No Yes 
Age at last follow 
up 
31 years 14 years 8 years 




HbF, hemoglobin F; MCV, red blood cell mean corpuscular volume; U/K, unknown; MRI, magnetic resonance 
imaging; CNS, central nervous system; WISC-IV (Wechsler Intelligence Scale for Children-Fourth Edition) test; 
AST, aspartate amino transferase; ALT, alanine aminotransferase; GH, growth hormone; SD, standard deviation; 
NA, not available; IU, international unit. 
 
 
 
 
 





